)
)
Mink Therapeutics Investor Relations Material
Latest events
Q2 2024
Mink Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Mink Therapeutics Inc
Access all reports
MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing allogeneic, off-the-shelf, invariant natural killer T cell therapies for the treatment of cancer and other immune-mediated diseases. Our lead product candidate, MM-111, is an investigational iNKT cell receptor agonist being studied in several ongoing clinical trials in Japan and the United States. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.
Latest articles
)
Cristiano Amon: Qualcomm's 5G Specialist CEO
Cristiano Amon, Qualcomm CEO, has spent two decades at the company while taking on several roles, developing both technical and business expertise.
16 Sep 2024
)
Qualcomm: Quality Communication and Semiconductor Innovation
Founded in 1985, Qualcomm has transformed the digital communication industry with CDMA technology and its advanced semiconductor business.
13 Sep 2024
)
Strong Opinions, Loosely Held: Pontus Dackmo on Flexibility and Market Psychology
After a two-decade career in finance, Pontus Dackmo co-founded Protean Funds Scandinavia in 2022, where he now serves as CEO and Investment Manager.
4 Sep 2024
Ticker symbol
INKT
Country
🇺🇸 United States